Although the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely due to the drug's action on the CNS. Aldopa is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, total peripheral resistance, and blood pressure. Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug's antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine (dopa)- the precursor of norepinephrine, 5-hydroxytryptophan (5-HTP), serotonin (in the CNS) and in most peripheral tissues.
Aldopa is used for Hypertension
Aldopa is also used to associated treatment for these conditions: High Blood Pressure (Hypertension), Hypertensive crisis
|Other Names||Alpha medopa, alpha-Methyl dopa, Alphamethyldopa, L-alpha-Methyldopa, L-Methyl Dopa, Methyl dopa, Methyldopa, metildopa|
|Weight||250mg, 100mg+10mg, 250mg+25mg|
Methyldopa is less than 15% bound to plasma proteins and its primary metabolite, O-sulfate metabolite, is about 50% protein bound. Following intravenous administration, approximately 17% of the dose in normal subjects were circulating in the plasma as free methyldopa.
|Therapeutic Class||Centrally acting antihypertensive drugs (central sympatholytic)|
|Manufacturer||Lincoln Pharmaceuticals Ltd, Irza Pharma (pvt) Ltd,, Albion Pharmaceuticals Ltd|
|Available Country||India, Pakistan, Bangladesh|
|Last Updated:||June 23, 2021 at 9:00 am|
Table Of contents
Initiation of Therapy: The usual starting dosage of Aldopa is 250 mg two or three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than two days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening. When Aldopa is given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When Aldopa is given with antihypertensives other than thiazides, the initial dosage of Aldopa should be limited to 500 mg daily in divided doses; when Aldopa is added to a thiazide, the dosage of thiazide need not to be changed.
Maintenance Therapy: The usual daily dosage of Aldopa is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 gm. Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of Aldopa frequently will restore effective control of blood pressure. A thiazide may be added at any time during Aldopa therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 gm of Aldopa daily. Aldopa is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses.
Initial dosage is based on 10 mg/kg of body weight daily in two to four doses. The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 gm daily, whichever is less.
Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. The following systemic side effects may rarely occurs with the use of Aldopa - angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. However, significant adverse effects due to Aldopa have been infrequent and this agent usually is well tolerated.
Patient with history of haemolytic anaemia, liver disease or depression; parkinsonism, hepatic porphyria. Not intended for the treatment of phaeochromocytoma. Renal or hepatic impairment. Childn, elderly. Pregnancy and lactation.
When Aldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. Patients may require reduced doses of anesthetics when on Aldopa. When Aldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. Coadministration of Aldopa with ferrous sulfate or ferrous gluconate is not recommended.
- Take with or without food. Drug pharmacokinetics is unaffected.
Volume of Distribution
The apparent volume of distribution ranges between 0.19 and 0.32L/kg and the total volume of distribution ranges from 0.41 to 0.72L/kg. Since methyldopa is lipid-soluble , it crosses the placental barrier, appears in cord blood, and appears in breast milk.
The plasma half-life of methyldopa is 105 minutes. Following intravenous injection, the plasma half-life of methyldopa ranges from 90 to 127 minutes.
The renal clearance is about 130 mL/min in normal subjects and is decreased in patients with renal insufficiency.
Pregnancy & Breastfeeding use
Pregnancy Category B. Aldopa appears in breast milk. Therefore, caution should be exercised when Aldopa is given to a nursing woman.
Aldopa is contraindicated in patients with:
- active hepatic disease, such as acute hepatitis and active cirrhosis.
- liver disorders previously associated with Aldopa therapy.
- hypersensitivity to any component of these products.
- On therapy with monoamine oxidase (MAO) inhibitors.
Pediatric Use: There are no well-controlled clinical trials in pediatric patients. Information on dosing in pediatric patients is supported by evidence from published literature regarding the treatment of hypertension in pediatric patients.
Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, lightheadedness, constipation, distention, flatus, diarrhea, nausea, vomiting). In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or emesis may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion.